Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Immune checkpoints are critical regulators of immune responses, often exploited by tumors to evade immune detection.
• Checkpoint blockade therapies targeting PD-1 and CTLA-4 have revolutionized cancer treatment, primarily by enhancing T cell activity.
• Emerging evidence indicates that immune checkpoints are also expressed on Natural Killer (NK) cells, suggesting broader therapeutic potential.

Purpose of the Study:

• To review current knowledge on targetable NK cell inhibitory receptors.
• To explore the role of these receptors in NK cell-mediated anti-cancer immunity.
• To discuss the implications for developing novel NK cell-based cancer immunotherapies.

Main Methods:

• Literature review of scientific publications on immune checkpoints and NK cell biology.
• Analysis of data on receptor expression and function in cancer.
• Synthesis of information regarding therapeutic strategies targeting NK cell checkpoints.

Main Results:

• Several NK cell inhibitory receptors, including KIRs, NKG2A, TIGIT, CD96, CD112R, PD-1, TIM-3, LAG-3, IL-1R8, CD161, and Siglecs, are identified as potential therapeutic targets.
• These receptors modulate NK cell responses to cancer, offering new avenues for immune evasion or activation.
• Understanding these pathways is crucial for optimizing cancer immunotherapy.

Conclusions:

• Targeting NK cell inhibitory receptors represents a promising strategy to enhance cancer immunotherapy beyond T cell-based approaches.
• Further research into these receptors could lead to the development of more effective and broadly applicable cancer treatments.
• The review provides a comprehensive overview of targetable NK cell checkpoints for future therapeutic interventions.